Asundexian may reduce recurrent ischemic stroke without increased bleeding risk

1. In this randomized controlled trial involving patients with recent noncardioembolic ischemic cerebrovascular accident, asundexian in combination with antiplatelet therapy reduced recurrent ischemic stroke compared to antiplatelet therapy alone.

2. There was no significant difference in major bleeding between the two groups.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Recurrent ischemic stroke remains a major clinical challenge despite widespread use of antiplatelet therapy, with substantial long-term risks of disability and death. Traditional escalation to dual antiplatelet therapy improves early outcomes but is limited by bleeding risk, particularly with prolonged use. Factor XI has emerged as a promising therapeutic target because it appears to contribute more to pathologic thrombosis than to normal hemostasis, raising the possibility of safer anticoagulation strategies. This large, randomized controlled trial evaluated whether adding the factor XIa inhibitor asundexian to standard antiplatelet therapy could improve secondary stroke prevention. The study found that asundexian lowered the risk of recurrent ischemic stroke and major cardiovascular events compared to placebo. Importantly, this benefit was achieved without a meaningful increase in major bleeding or intracranial hemorrhage, addressing a key limitation of other antithrombotic strategies. Study strengths included the large, globally diverse population, early enrollment after stroke, and inclusion of a broad range of stroke severities and treatment strategies. However, the study was limited by relatively few patients with more severe strokes, limited representation of certain demographic groups, and significant rates of treatment discontinuation. Nonetheless, these findings suggest that asundexian may be effective for reducing the risk of secondary ischemic stroke.

Click to read the study in NEJM

Relevant Reading: One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke

In-Depth [randomized controlled trial]: This phase 3, double-blind, randomized controlled trial (OCEANIC-STROKE) evaluated the efficacy and safety of asundexian, an oral factor XIa inhibitor, in patients with recent noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). A total of 12,327 patients were enrolled within 72 hours of symptom onset and randomized in a 1:1 fashion to receive asundexian 50 mg daily or placebo, in addition to background single or dual antiplatelet therapy. Randomization was stratified by intended antiplatelet regimen, and patients were followed for a median duration of 567 days. The primary efficacy outcome, recurrent ischemic stroke, occurred in 6.2% of patients receiving asundexian compared to 8.4% in the placebo group, corresponding to a hazard ratio (HR) of 0.74 (95% confidence interval [CI], 0.65 to 0.84; p<0.001). Secondary outcomes also favored the asundexian group, including a reduction in the composite of cardiovascular death, myocardial infarction, or stroke (9.2% vs. 11.1%; HR, 0.83; p<0.001) and in any stroke (6.6% vs. 8.8%; HR, 0.74; p<0.001). However, the reduction in ischemic stroke within the first 90 days did not reach statistical significance (HR, 0.84; p=0.08), suggesting that treatment effects may accrue over longer follow-up. The primary safety outcome, major bleeding, was similar between groups (1.9% vs. 1.7%; HR, 1.10; 95% CI, 0.85 to 1.44). Rates of intracranial hemorrhage, hemorrhagic stroke, and fatal bleeding were also comparable. Subgroup analyses were consistent across age, sex, stroke subtype, and use of dual antiplatelet therapy. Overall, asundexian was associated with superior secondary ischemic stroke prevention, particularly later in treatment, without increased risk of major bleeding.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.